Livcare 5 mg (Tablet)
Unit Price: ৳ 30.00 (2 x 10: ৳ 600.00)
Strip Price: ৳ 300.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Obeticholic acid |
| Company | Aristopharma ltd |
| Also available as |
Indications
- Treatment of primary biliary cholangitis without cirrhosis
- Treatment of primary biliary cholangitis with compensated cirrhosis
- Combination therapy with ursodeoxycholic acid (UDCA)
- Monotherapy in patients unable to tolerate UDCA
Pharmacology
- Agonist for Farnesoid X Receptor (FXR)
- Regulator of bile acid, inflammatory, fibrotic, and metabolic pathways
- Reduction of intracellular hepatocyte bile acid concentrations
- Increase in bile acid transport out of hepatocytes
- Increase in FGF-19 concentrations
Dosage & Administration
- Recommended starting dosage of 5 mg once daily for the first 3 months
- Maximum dosage of 10 mg once daily after 3 months based on tolerability
- Monitoring for biochemical response and tolerability
- Management of intolerable pruritus
Interaction
- Interaction with bile acid binding resins
- Interaction with warfarin
- Potential increase in exposure to CYP1A2 substrates
- Potential interactions with inhibitors of Bile Salt Efflux Pump
Contraindications
- Decompensated cirrhosis
- Compensated cirrhosis with evidence of portal hypertension
- Complete biliary obstruction
Side Effects
- Pruritus
- Fatigue
- Stomach pain
- Rash
- Arthralgia
- Oropharyngeal pain
- Dizziness
- Constipation
- Abnormal thyroid function
- Eczema
Pregnancy & Lactation
- Limited human data on use during pregnancy
- Animal studies showing no developmental abnormalities
- No information on presence in human milk
- Consideration of benefits of breastfeeding
Precautions & Warnings
- Risk of hepatic decompensation and failure in patients with cirrhosis
- Potential for severe pruritus
- Reduction in HDL-C levels
- Monitoring of serum lipid levels
- Consideration of risks and benefits after 1 year of treatment
Use in Special Populations
- Lack of established safety and effectiveness in pediatric patients
- 20% of patients in clinical trials aged 65 years and older
- Contraindicated in patients with hepatic impairment
Overdose Effects
- Dose-dependent increase in hepatic adverse reactions
- Incidence of liver biochemical test elevations
- Ascites, jaundice, and portal hypertension
Therapeutic Class
- Farnesoid X Receptor Agonists
Storage Conditions
- Store below 30°C
- Keep in a dry place
- Protect from light
- Keep out of children's reach